Wilex AG has announced plans to raise approximately €17.3 million in cash, and to convert an existing loan into equity, ahead of a meeting with the FDA to discuss a further development strategy for its cancer diagnostic Redectane. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
